{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"To determine whether repeated bone marrow samples analyzed for gene expression profiling (GEP) can identify genes related to drug resistance in myeloma. The drug resistant genes or the gene products might then be targeted specifically to eradicate myeloma cells surviving tandem transplantation.","groups":[{"description":"This was a single arm study for myeloma patients with \\<12 months of prior treatment to determine whether the incorporation of bortezomib into a tandem transplant regimen followed by 2 years of maintenance therapy would increase event-free survival.","id":"OG000","title":"Tandem Transplant in MM <12 Mos of Prior Treatment"}],"populationDescription":"Enrollment halted prematurely. Study met stopping rules (3 or more of the first 20 participants died due to treatment-related toxicity).\n\nData for outcome measure 2 were not collected.","reportingStatus":"POSTED","timeFrame":"5 years","title":"Identification of Drug Resistant Genes","type":"PRIMARY"}